{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:19:25Z","timestamp":1783448365256,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Accumulating evidence supports switching virologically suppressed people with HIV (PWH) harbouring nucleoside reverse transcriptase inhibitor (NRTI) resistance\u2010associated mutations (RAMs) to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF). However, real\u2010world data on initiating B\/F\/TAF in individuals with NRTI RAMs and ongoing viremia remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included adult PWH treated at the Second Hospital of Nanjing between June 2020 and November 2024 who had at least one NRTI RAM and an HIV\u20101 RNA \u2265200 copies\/mL at B\/F\/TAF initiation. The primary outcome was virological suppression at 12\u2009months (HIV\u20101 RNA &lt;50 copies\/mL). Laboratory adverse events were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 45 participants were included (97.8% male). At baseline, the median HIV\u20101 RNA was 36\u2009800 copies\/mL (interquartile range [IQR]: 5130\u2013243\u2009000), and the median CD4 cell count was 53 cells\/\u03bcL (IQR: 18\u2013307). AIDS\u2010defining illnesses were documented in 13 participants (28.9%). M184V\/I was present in 71.1% and K65R\/N in 8.9%. At 12\u2009months, 41\/45 (91.1%) participants achieved HIV\u20101 RNA &lt;50 copies\/mL, and 44\/45 (97.8%) achieved &lt;200 copies\/mL, with high suppression rates across resistance subgroups, including those with K65R\/N or thymidine analogue mutations. All participants without suppression at 12\u2009months achieved virological suppression with extended follow\u2010up. Grade 3\u20134 laboratory adverse events occurred in 10\/45 (22.2%) participants, most commonly severe bone marrow suppression. These events were frequently attributable to comorbidities and concomitant medications, with no discontinuations of B\/F\/TAF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B\/F\/TAF demonstrated high virological suppression and acceptable laboratory safety in viremic PWH with pre\u2010existing NRTI RAMs, supporting its use in this challenging clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70249","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:56:06Z","timestamp":1777384566000},"page":"1196-1202","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide in viremic people with\n                    <scp>HIV<\/scp>\n                    harbouring\n                    <scp>nucleos(t)ide reverse transcriptase inhibitor<\/scp>\n                    resistance\u2010associated mutations"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5524-0524","authenticated-orcid":false,"given":"Zheng","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Public Health Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Qin","sequence":"additional","affiliation":[{"name":"Clinical Research Center, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Research Center, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Hospital of Nanjing Nanjing University of Chinese Medicine  Nanjing China"},{"name":"School of Public Health Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf159"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102859"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S391296"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.02.005"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00092-3"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101609"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00516-8"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003317"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.06.027"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.11.012"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13376"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02916-2"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00572-6"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2428-3"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2540"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf162"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70249","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:09:10Z","timestamp":1783447750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/hiv.70249"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70249","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2026-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}